openPR Logo
Press release

PharmaPoint: Chronic Obstructive Pulmonary Disease - Global Drug Forecast and Market Analysis to 2025

06-13-2017 01:56 PM CET | Health & Medicine

Press release from: Pharmaceutical Market Reports - MRH

Market Research HUB

Market Research HUB

Chronic obstructive pulmonary disease (COPD) is a progressive lung disease characterized by an abnormal inflammatory response and airflow obstruction that is not fully reversible. Chronic airflow limitation is caused by both small airway diseases, such as obstructive bronchiolitis, as well as parenchymal destruction, including emphysema. Research suggests that the pathogenesis of COPD involves both genetic and environmental factors. The fourth leading cause of death in the world, COPD progresses slowly and symptoms, including shortness of breath, wheezing, chest tightness, cough, and increased mucous production, worsen over time. Although it is currently unknown if the damage to the airways and lungs can be reversed, treatments and lifestyle changes can help slow the progress of the disease.

Request Free Sample Report - http://www.marketresearchhub.com/enquiry.php?type=S&repid=1142784

GlobalData estimates the 2015 sales for the COPD market at approximately $9.9 billion across the 8MM, encompassing the US, the five major European Union countries (5EU: France, Germany, Italy, Spain, and UK), Japan, and Australia. Over the course of the 10-year forecast period, the COPD market will grow at a Compound Annual Growth Rate (CAGR) of 3.7% across the 8MM. Each of the 8MM are anticipated to grow significantly, recording CAGRs of 3.7%, 5.2%, 4.3%, and 6.6% across the US, 5EU, Japan, and Australia, respectively. At the end of 2025, the US will account for 77.8% of sales across the 8MM, while the 5EU, Japan, and Australia will account for around 19.2%, 2.4%, and 0.7% of sales, respectively. The higher sales numbers for the US can be attributed to the higher prices of pharmaceuticals and the greater diagnosed prevalence of COPD in the region, as well as the anticipated high annual cost of therapy (ACOT) of GSK’s Nucala and AstraZeneca’s benralizumab in the US market.

Key Questions Answered

How will the COPD market landscape in the 8MM (US, France, Germany, Italy, Spain, UK , Japan, and Australia) change from 2015–2025?

What are the most promising late-stage pipeline drugs in COPD?

How do the clinical and commercial attributes of late-stage pipeline therapies compare with one another, and against existing treatment options?

What are the greatest unmet needs in COPD? Will the pipeline drugs fulfil these needs of the market?

What are the largest opportunities in the COPD landscape?

Scope

Overview of COPD, including epidemiology (mMRC and CAT patient population), etiology, pathophysiology, symptoms, diagnosis, and current management strategies.

Topline COPD market revenue from 2015–2025. ACOT and major pipeline product sales in this forecast period are included.

Key topics covered include current treatment options, unmet needs and opportunities, and the drivers and barriers affecting COPD therapeutics sales in the 8MM.

Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.

Analysis of the current and future market competition in the global COPD therapeutics market. Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Browse Full Report with TOC - http://www.marketresearchhub.com/report/pharmapoint-chronic-obstructive-pulmonary-disease-global-drug-forecast-and-market-analysis-to-2025-report.html

Reasons to buy

The report will enable you to:

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

Develop business strategies by understanding the trends shaping and driving the global COPD therapeutics market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the COPD therapeutics market in the future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Companies mentioned

AstraZeneca
Boehringer Ingelheim
Chiesi
GSK
Novartis
Sunovion

Make an Enquiry - http://www.marketresearchhub.com/enquiry.php?type=enquiry&repid=1142784

About Market Research Hub

Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

Contact Us
90 State Street,
Albany, NY 12207,
United States
Toll Free : 866-997-4948 (US-Canada)
Tel : +1-518-621-2074
Email : press@marketresearchhub.com
Website : http://www.marketresearchhub.com/
Read Industry News at - https://www.industrynewsanalysis.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release PharmaPoint: Chronic Obstructive Pulmonary Disease - Global Drug Forecast and Market Analysis to 2025 here

News-ID: 576183 • Views: 209

More Releases from Pharmaceutical Market Reports - MRH

Global Active Pharmaceutical Ingredients Market Size, Growth, Share, Trends and …
Market Research Hub includes new market research report "Global Active Pharmaceutical Ingredients Market Research Report 2017-2022 by Players, Regions, Product Types & Applications" to its huge collection of research reports. The global Active Pharmaceutical Ingredients market is valued at XX million USD in 2016 and is expected to reach XX million USD by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Request Free Sample Report -
Global and Chinese Carfentanil Expedient Market Outlook and Profitable Forecasts …
The carfentanil market is witnessing huge developments in the veterinary and other chemical research sectors. Looking into this development, a new report has been added to the vast online repository of Market Research Hub (MRH), with the title ‘’Global and Chinese Carfentanil Market Outlook 2017-2022‘’. The study offers a precise evaluation of the most positive business factors such as biggest players and regions; as well as a prospective forecast till
Global Propofol Sales Market Size, Share, Growth, Trends and Forecast
According to the report "Global Propofol Sales Market Report 2017" added by Market Research HUB, the global Propofol market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split global into several key Regions, with sales (K MT), revenue (Million USD), market share and growth rate
Global Mammalian Cell Culture Sales Market Size, Share, Trends and Forecast
According to the report "Global Mammalian Cell Culture Sales Market Report 2017" added by Market Research HUB, the global Mammalian Cell Culture market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split global into several key Regions, with sales (K MT), revenue (Million USD), market

All 5 Releases


More Releases for COPD

COPD Therapeutics Global Market Research Report 2019
COPD Therapeutics Report by Material, Application, and Geography � Global Forecast to 2022 is a professional and in-depth research report on the world's major regional market conditions, focusing on the main regions (North America, Europe and Asia-Pacific) and the main countries (United States, Germany, united Kingdom, Japan, South Korea and China). Access more details about this report at: https://www.research2reports.com/report-medical-devices/copd-therapeutics-market/80858 The report firstly introduced the COPD Therapeutics basics: definitions, classifications, applications and market
Asthma and COPD Drugs Market worth $50,359 Million by 2022
"The key players of the Global COPD and asthma drugs market are employing novel concepts and ideas to improve, manage and control asthma & COPD, and also enhance their profitability so as to gain a competitive edge over the other market players. Seretide/Advair, Symbicort, and Singular were leading brands and accounted for around one-fourth share in world COPD and asthma drugs market." Global Asthma and COPD Drugs Market was valued at
Alarming Prevalence of COPD to Propel Oxygen Therapy Devices Market
"Oxygen therapy equipment market driven by increasing urbanization and rising levels of air pollution." An intelligence report on the global oxygen therapy equipment market has been added to the burgeoning portfolio of MarketResearchReports.biz. Titled, “Global Oxygen Therapy Equipment Market - Analysis By Product, Portability, Application, Region, Country: Opportunities and Forecast (2017- 2022) - By Product (Oxygen Concentrators, Liquid Oxygen Devices and Oxygen Cylinders), By Portability (Stationary, Portable Devices), By Application (COPD,
Asthma and COPD Drugs Market | Key Opportunities And Forecast 2024
The top five companies in the U.S. and China Asthma And Copd Drugs Market accounted for just under 64.0% in 2015, hinting at not just the consolidated nature of this industry but also at the immense competition among players. GlaxoSmithKline plc, Astrazeneca plc, Boehringer Ingelheim, Merck & Co. Inc., and Novartis AG currently enjoy the leading spots in the asthma and COPD drugs market. According to Transparency Market Research, the opportunity
Global COPD and Asthma Devices Market Size
According to a new report, Global COPD and Asthma Devices Market, published by KBV Research, The Global COPD and Asthma Devices Market attained a market size of $ 27,465.1 Million in 2015 and is expected to reach $ 39,051.4 Million by 2022 growing at a CAGR of 5.2 % CAGR during 2016 – 2022. The Asia Pacific market dominated the Global COPD and Asthma Devices Market in 2015 and would
COPD Drug Market Opportunity & Clinical Pipeline Analysis
Close to 1 Billion people worldwide suffer from respiratory or pulmonary diseases. In the respiratory therapeutic domain, Asthma and COPD are the major categories, accounting for close to 75% of the total patient for respiratory or pulmonary diseases. Chronic obstructive pulmonary disease (COPD) is a disease which progresses in the lungs and requires treatment all through the life. It is an inflammatory disorder which is characterized by obstruction in the